Project Grant R21CA302730
Award Date 8/8/25
Completion Date 7/31/27
Dollars Obligated $409K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- This federal Project Grant award of $166,800.00 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research at Pennsylvania State University's Milton S. Hershey Medical Center to investigate a novel combination therapy approach for an aggressive subtype of lung adenocarcinoma. The research aims to characterize how the loss of the MTSS1 protein impacts the tumor immune microenvironment in SMARCA4-mutant lung adenocarcinoma, and evaluate the...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to New York University School of Medicine provides $696,569.00 in funding to advance research on a novel therapy for lung cancer. The research aims to characterize the role of the protein lipocalin 2 (LCN2) in the tumor microenvironment and develop antibody-based therapeutics that interfere with LCN2 function, both as monotherapy and in combination with immune checkpoint blockade. This 5-year...
- The University of Illinois was awarded a $160,330 Project Grant from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) with a performance period of December 1, 2024 to November 30, 2026. The project seeks to develop novel human-relevant lung adenocarcinoma models by genome editing primary human lung stem and progenitor cells, and culturing them as tumor organoids or orthotopically xenografting them into mice. The goal is to create models that more accurately reflect...
- The University of Southern California received a $650,450 Project Grant from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to develop a novel lung cancer immunotherapy product. The grant will fund the translational development of a tumor-specific T cell receptor-engineered CD4+ T cell product targeting the CT83 cancer-testis antigen, which is expressed in 40-60% of non-small cell lung cancers. The project aims to improve the therapeutic potential of this...
- This $557,418 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on March 17, 2025 to The Trustees of Columbia University in the City of New York for the project "Targeting SMARCA2 in SMARCA4-Deficient Lung Cancers In Vivo". The project aims to mechanistically evaluate SMARCA2 degradation as a therapeutic approach for treating SMARCA4-deficient lung adenocarcinomas, which account for ~20,000 new lung cancer cases annually in the...
- This Project Grant award of $153,959.00 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of a bispecific fusion protein, APD1-4-1BBL, designed to enhance the safety and efficacy of cancer immunotherapy treatments. The fusion protein is engineered to disrupt the PD-1/PD-L1 interaction while harnessing PD-1 binding to induce localized 4-1BB hyperclustering, which is expected to activate potent antitumor immunity. The award recipient, Auburn...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $315,246 to New York University School of Medicine to conduct research on breaking cytokine loops in lung adenocarcinoma, the leading subtype of lung cancer. The research aims to define how lung adenocarcinoma tumors with LKB1 mutations interact with the tumor microenvironment, including two specific cytokine signaling loops that promote tumor dedifferentiation and recruit...
- This federal Project Grant award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) provides $234,749 to The Ohio State University to conduct a multi-center Phase Ib clinical trial investigating the combination of the Hedgehog inhibitor Vismodegib and the anti-PD-L1 immunotherapy Atezolizumab in patients with metastatic non-small cell lung cancer (NSCLC). The goal is to understand how Hedgehog signaling in tumor-associated macrophages (TAMs) impacts CD8+...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,773 to the University of Maryland, Baltimore to develop an engineered prodrug that selectively delivers a potent cytotoxin to tumor cells expressing hyperactive membrane-anchored serine proteases. The goal is to create an effective therapeutic strategy to target metastatic solid tumors, including ovarian, lung, and colon cancers, which often respond poorly to current...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....